BioDelivery Sciences International Inc logo

BDSI - BioDelivery Sciences International Inc News Story

$3.06 -0.1  -3.7%

Last Trade - 3:06pm

Sector
Healthcare
Size
Small Cap
Market Cap £227.2m
Enterprise Value £203.7m
Revenue £110.8m
Position in Universe 4065th / 6853

BRIEF-BioDelivery sciences announces patent litigation settlement agreement with Teva

Thu 12th October, 2017 12:00pm
Oct 12 (Reuters) - Biodelivery Sciences International Inc 
 BDSI.O  
    * BioDelivery Sciences announces patent litigation 
settlement agreement with Teva 
    * BioDelivery Sciences International Inc - other terms of 
agreement are confidential 
    * BioDelivery Sciences - as part of settlement agreement, 
co has entered into a non-exclusive license agreement with Teva 
 
    * BioDelivery Sciences International -  entered into 
settlement agreement with Teva Pharmaceuticals USA, Actavis 
Laboratories Ut, Teva Pharmaceuticals Industries 
    * BioDelivery Sciences International Inc - as part of 
settlement agreement BDSI has entered into a non-exclusive 
license agreement with Teva 
    * BioDelivery Sciences - settlement agreement permits Teva 
to first begin selling its generic version of BUNAVAIL in U.S. 
On July 23, 2028 or earlier under certain circumstances 
    * BioDelivery Sciences International -  settlement 
agreement resolves BDSI's BUNAVAIL patent litigation against 
Teva pending in United States district court 
    * BioDelivery Sciences - agreement with Teva permits Teva 
to first begin selling generic version of BUNAVAIL in U.S. On 
July 23, 2028 or earlier 
 
Source text for Eikon:  ID:nPn3nqJMBa  
Further company coverage:  BDSI.O  
 
 ((Bangalore.newsroom@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.